Literature DB >> 12924748

The Clinical Opiate Withdrawal Scale (COWS).

Donald R Wesson1, Walter Ling.   

Abstract

The clinical opiate withdrawal scale (COWS) is a clinician-administered, pen and paper instrument that rates eleven common opiate withdrawal signs or symptoms. The summed score of the eleven items can be used to assess a patient's level of opiate withdrawal and to make inferences about their level of physical dependence on opioids. With increasing use of opioids for treatment of pain and the availability of sublingual buprenorphine in the United States for treatment of opioid dependence, clinical assessment of opiate withdrawal intensity has received renewed interest. Buprenorphine, a partial opiate agonist at the mu receptor, can precipitate opiate withdrawal in patients with a high level of opioid dependence who are not experiencing opioid withdrawal. Since development of the first opiate withdrawal scale in the mid-1930s, many different opioid withdrawal scales have been used in clinical and research settings. This article reviews the history of opiate withdrawal scales and the context of their initial use. A template version of the COWS that can be copied and used clinically is appended. PDF formatted versions of the COWS are also available from the websites of the American Society of Addiction Medicine, the California Society of Addiction Medicine, the UCLA Integrated Substance Abuse Programs, and AlcoholMD.com.

Entities:  

Mesh:

Year:  2003        PMID: 12924748     DOI: 10.1080/02791072.2003.10400007

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  248 in total

1.  Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Authors:  E C Strain; J A Harrison; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

3.  Comparing buprenorphine induction experience with heroin and prescription opioid users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Larissa Mooney; Jacqueline Fahey; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-02-01

4.  Improving temporal efficiency of outpatient buprenorphine induction.

Authors:  Erik W Gunderson; Frances R Levin; Margaret M Rombone; Suzanne K Vosburg; Herbert D Kleber
Journal:  Am J Addict       Date:  2011-07-18

5.  Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy.

Authors:  E Sherwood Brown; Carlos Tirado; Abu Minhajuddin; Maureen Hillhouse; Bryon Adinoff; Walter Ling; Geetha Doraimani; Christie Thomas
Journal:  J Ethn Subst Abuse       Date:  2010       Impact factor: 1.507

6.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

Review 7.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

8.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

9.  Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.

Authors:  Iuliia Makarenko; Iryna Pykalo; Sandra A Springer; Alyona Mazhnaya; Ruthanne Marcus; Sergii Filippovich; Sergii Dvoriak; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2019-05-10

10.  Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

Authors:  Jennifer R Schroeder; Karran A Phillips; David H Epstein; Michelle L Jobes; Melody A Furnari; Ashley P Kennedy; Markus Heilig; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2018-08-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.